Overall, additional future preclinical research is needed to better understand how CDK9 functions in normal and cancer cells to ultimately define the therapeutic applicability of CDK9 inhibitors as single or adjuvant anti-cancer molecules. The gene discussed is CDK9; the disease is cancer.